Biology subjects

Sand, J. M. B.

Publications and source records attributed to Sand, J. M. B..

3 recordsLinked to original sources

bioRxiv2026

Circulating biomarkers reflecting type III, IV and VI collagen remodeling are present in lung tissue of patients with pulmonary fibrosis and non-fibrotic controls

BackgroundThe extracellular matrix (ECM) is a dynamic network that provides structural support and maintains tissue homeostasis. Collagens are the main structural components of the ECM, occupying distinct tissue compartments and serving specialized roles. Dysregulated ECM remodeling involves an imbalance between collagen production and degradation, generating neoepitope-specific fragments that can be released into circulation. Serological measurements of these fragments can be used as biomarkers of disease and have been associated with progression and mortality in different fibrotic diseases, including pulmonary fibrosis (PF). This study aimed to investigate whether these systemic biomarkers originate from human lung tissue in patients with PF and non-fibrotic controls. MethodsLung tissue was collected from patients with PF (n = 21) and non-fibrotic controls (n = 21) and processed in parallel as formalin-fixed paraffin-embedded or snap-frozen samples. Serum samples were collected from patients with PF and healthy controls (n = 21). Neoepitope-specific biomarkers reflecting type III, IV, and VI collagen production (PRO-C3, PRO-C4, and PRO-C6) and degradation (C3M, C4M, C4Ma3, and C6M) were quantified in serum and proteolytically degraded lung tissue, and their spatial distribution was assessed by immunohistochemistry in lung tissue sections. ResultsAll collagen remodeling biomarkers were significantly increased in serum of patients with PF compared with healthy controls (PRO-C3: p = 0.0006, all others: p < 0.0001). Collagen degradation fragments (C3M, C4M, and C6M) could be generated and released from both non-fibrotic and fibrotic human lung tissue following proteolytic cleavage with pepsin, collagenase, and/or MMP-9. All biomarkers were detected in lung tissue by immunohistochemical staining, with widespread distribution of type III and IV collagen fragments, whereas type VI collagen (PRO-C6) production showed a more compartment-specific pattern. ConclusionsThese findings demonstrated that neoepitope-specific collagen remodeling biomarkers, usually detected in circulation, are present and can be released from human lung tissue. Their spatial distribution suggests that ECM remodeling is heterogeneous and differs according to collagen type and distinct tissue compartments. Collectively, our findings support the use of collagen remodeling biomarkers as tools to assess ECM remodeling in pulmonary disease.

molecular biology↗

bioRxiv2026

Type VI collagen is proportionally lower around airways and blood vessels in idiopathic pulmonary fibrosis

Type VI collagen (COL6) is a key extracellular matrix protein that supports matrix organization and cell-matrix interactions, yet its regulation in idiopathic pulmonary fibrosis (IPF) remains poorly understood. Here, we characterize COL6 gene expression, spatial localization, remodeling, and functional effects of COL6-derived fragments. Analysis of publicly available single-cell RNA sequencing data from 30 controls and 32 pulmonary fibrosis patients revealed higher expression of COL6A1-A6 in fibrotic lungs, predominantly in mesenchymal cells (A1: p=0.0002, A2: p=0.0005, A3: p=2.5x10-5, A5: p=0.016, A6: p=0.007). Immunohistochemical analysis of lung tissue from never-smoker (n=9), ex-smoker (n=9) controls, and IPF patients (n=12) showed extensive COL6 localization across parenchyma, airways, and vessels. The proportion of COL61 and COL62 was lower around IPF vessels (1: p<0.001, 2: p=0.012), and COL62 was lower around IPF airways (p=0.033) compared with never-smokers. Quantification of COL6 remodeling fragments in lung tissue from never-smoker (n=3), ex-smoker (n=5) controls, and IPF patients (n=10) revealed that COL6 production (PRO-C6) localized around airways and vessels but was proportionally lower in IPF airways (never-smokers: p=0.0075). In contrast, COL6 degradation (C6M) was widely distributed throughout the tissue, with lower levels in IPF (never-smokers: p=0.0008). Functionally, COL6 and PRO-C6 increased fibroblast viability (COL6: p=0.002, PRO-C6: p=0.0021), while apoptosis was unaffected. Similar trends were observed in epithelial and endothelial cells. In summary, despite increased COL6 gene expression, IPF lungs exhibited lower proportions of COL6 protein and synthesis around airways and vessels, suggesting disrupted matrix organization, altered remodeling, and pro-survival effects that may contribute to fibroblast persistence and fibrosis progression. New & NoteworthyIn this study, we revealed that IPF lungs are characterized by increased type VI collagen (COL6) gene expression but lower COL6 protein and turnover proportions around airways and blood vessels compared with controls. COL6 and a fragment associated with its production (PRO-C6) increased lung fibroblast viability. These findings highlight that pulmonary fibrotic tissue is characterized by disrupted extracellular matrix and altered tissue remodeling and suggest that COL6 may contribute to fibroblast persistence and fibrosis progression.

molecular biology↗

bioRxiv2024

Extracellular Matrix-Induced Genes May Reduce Response to Rapamycin in LAM

RationaleLymphangioleiomyomatosis (LAM) is a rare cystic lung disease driven by nodules containing TSC2-/- LAM cells and recruited LAM associated fibroblasts (LAFs). Although rapamycin reduces lung function loss, some patients continue to decline meaning additional therapies are needed. ObjectivesTo investigate how the LAM nodule environment affects LAM cell proliferation and the response to rapamycin. MethodsChanges in advanced LAM were identified using shotgun proteomics and immunohistochemistry in tissue from carefully phenotyped patients. Genes potentially associated with rapamycin insensitivity of cells grown on LAF-derived extracellular matrix were identified by RNA sequencing and validated using repurposed pharmacologic inhibitors. Main ResultsMore advanced disease was associated with increasing nodules adjacent to lung cysts and greater decline in forced expiratory volume in 1 sec (FEV1) when treated with rapamycin (p=0.005). In late-stage LAM, proteomics identified upregulation of pathways associated with accumulation of activated fibroblasts, including extracellular matrix deposition, glucose metabolism and the actin cytoskeleton. Picrosirius red staining and immunohistochemistry confirmed deposition of extracellular matrix within LAM nodules. The growth of TSC2-/- model LAM cells was increased on LAF-derived extracellular matrix (LAF ECM), and incompletely supressed by rapamycin (p<0.0001). RNA sequencing of cells grown on LAF ECM identified upregulation of pathways driving cell cycle control, transcription and metabolism in cells. Tractable, pro-proliferative, rapamycin insensitive genes included CDK7, GAS6 and PLAU. Repurposed inhibitors of these pathways inhibited LAM cell proliferation and enhanced the anti-proliferative effect of rapamycin. ConclusionsExtracellular matrix deposited by LAM associated fibroblasts upregulates expression of genes which potentially blunt the response to rapamycin, but offer additional therapeutic opportunities for patients with established LAM.

cell biology↗